NERV
Minerva Neurosciences, Inc.
$4.74
+2.38%
$215.7M
No data for this timeframe.
Vol
Market Cap$215.7M
Cap SizeMicro Cap
Analyst ConsensusBuy (67%)
Inst. Holders5 funds
Inst. Value$1.7M
Inst. Activity2 buys / 0 sells
SEC Reports5
Press Releases2
Recent Activity
Jun 5, 2026
SEC
Minerva Neurosciences entered into an at-the-market (ATM) equity offering agreement with Leerink Partners to sell up to
8-K — Impact 6/10
Jun 3, 2026
Insider
Ahlholm Frederick W sold 680,000 shares
SVP, CFO and Secretary @ $0.00 ($0.00)
Jun 3, 2026
Insider
Kupfer David sold 50,000 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
VAN HEEK G JAN sold 50,000 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
other
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmator
May 5, 2026
SEC
Minerva Neurosciances reported Q1 2026 results with a GAAP net loss of $125.4M ($2.86/share) vs $3.8M ($0.50/share) a ye
8-K — Impact 4/10
Apr 23, 2026
SEC
Minerva Neurosciences, Inc. (NERV) filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, disclosing
DEFA14A — Impact 4/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
149,200 shares ($599.8K)
Price Targets
$9.50
+100.4% upside
Strong Buy
Current $4.74
Low $7.00
Median $7.50
High $14.00
3 analysts
$7.00
$14.00
Analyst Ratings
2Strong Buy
4Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 15, 2026 | Citizens | INITIATE | Market Outperform |
| Mar 12, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.01 ▲ +94.4% | $-0.01 — $-0.01 | 98% YoY | 1 |
| Next Q | $-0.01 ▲ +94.4% | $-0.01 — $-0.01 | 1 | |
| Current FY | $-0.20 ▲ +66.7% | $-0.20 — $-0.20 | 89% YoY | 1 |
| Next FY | $-0.80 ▼ -12.5% | $-0.95 — $-0.64 | 78% YoY | 2 |
Latest Reports
BEARISH
8-K
6/10
Minerva Neurosciences entered into an at-the-market (ATM) equity offering agreement with Leerink Partners to sell up to
Jun 5, 2026
NEUTRAL
8-K
4/10
Minerva Neurosciances reported Q1 2026 results with a GAAP net loss of $125.4M ($2.86/share) vs $3.8M ($0.50/share) a ye
May 5, 2026
NEUTRAL
Press
5/10
Minerva Neurosciences announced positive safety data from an open-label trial showing no clinically significant adverse
Mar 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.0M | — |
| RENAISSANCE TECHNOLOGIES LLC | $599.8K | ADD |
| TWO SIGMA INVESTMENTS, LP | $89.6K | NEW |
| MORGAN STANLEY | $44.4K | TRIM |
| BANK OF AMERICA CORP | $205.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Ahlholm Frederick | A | $0.00 |
| Jun 3, 2026 | Kupfer David | A | $0.00 |
| Jun 3, 2026 | VAN HEEK | A | $0.00 |
| Jun 3, 2026 | Kaul Inderjit | A | $0.00 |
| Jun 3, 2026 | HASLER HANS | A | $0.00 |
5 institutional holders with $1.7M total value (434,629 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 252,029 | $1.0M | 58.0% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 149,200 | $599.8K | 34.3% | ADD +28.1% |
| 3 | TWO SIGMA INVESTMENTS, LP | 22,294 | $89.6K | 5.1% | NEW |
| 4 | MORGAN STANLEY | 11,055 | $44.4K | 2.5% | TRIM -31.7% |
| 5 | BANK OF AMERICA CORP /DE/ | 51 | $205.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 116,500 | 149,200 | +28.1% | $599.8K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 22,294 | — | $89.6K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 875 | 10 | -98.9% | $21.00 | 2025-Q3 |
| UBS Group AG | TRIM | 1,621 | 875 | -46.0% | $1.5K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 25,764 | 12,915 | -49.9% | $22.0K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 16,104 | 11,004 | -31.7% | $18.7K | 2025-Q1 |
| UBS Group AG | DOUBLED | 12 | 1,621 | +13408.3% | $2.8K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 17,239 | 25,764 | +49.5% | $57.2K | 2024-Q4 |
| MORGAN STANLEY | ADD | 10,747 | 16,104 | +49.8% | $35.8K | 2024-Q4 |
| UBS Group AG | NEAR_EXIT | 10,552 | 12 | -99.9% | $27.00 | 2024-Q4 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Ahlholm Frederick W | SVP, CFO and Secretary | A | 680,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Kupfer David | Director | A | 50,000 | $0.00 | $0.00 |
| Jun 3, 2026 | VAN HEEK G JAN | Director | A | 50,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Kaul Inderjit | Director | A | 50,000 | $0.00 | $0.00 |
| Jun 3, 2026 | HASLER HANS PETER | Director | A | 50,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Luthringer Remy | CEO | A | 1,690,700 | $0.00 | $0.00 |
| Jun 3, 2026 | Laghrissi-Thode Fouzia | Director | A | 50,000 | $0.00 | $0.00 |
| Apr 21, 2026 | O'Connor James Joseph | Chief Business Officer and GC | A | 350,800 | $0.00 | $0.00 |
| Mar 31, 2026 | Kaul Inderjit | Director | A | 12,169 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 5.0/10.
BEARISH
8-K
6/10
Minerva Neurosciences entered into an at-the-market (ATM) equity offering agreement with Leerink Par
Jun 5, 2026
NEUTRAL
8-K
4/10
Minerva Neurosciances reported Q1 2026 results with a GAAP net loss of $125.4M ($2.86/share) vs $3.8
May 5, 2026
NEUTRAL
DEFA14A
4/10
Minerva Neurosciences, Inc. (NERV) filed a definitive proxy statement (DEFA14A) for its 2026 Annual
Apr 23, 2026
NEUTRAL
EFFECT
4/10
Minerva Neurosciences' shelf registration (Form S-3) has become effective, allowing the company to i
Mar 20, 2026
BEARISH
S-3
7/10
Minerva Neurosciences filed an S-3 shelf registration statement allowing it to raise up to $200 mill
Mar 11, 2026
Current analyst consensus: Buy (67% buy). Based on 9 analysts: 2 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.50 mean target
+100.4% upside
Strong Buy (2.67)
$7.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $4.74 |
| Target Low | $7.00 |
| Target Mean | $9.50 |
| Target Median | $7.50 |
| Target High | $14.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (2.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.01 | $-0.01 | $-0.01 | 97.7% | +94.4% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.01 | $-0.01 | $-0.01 | — | +94.4% | 1↑ 0↓ | $0.0B | — | 1 |
| Current FY 2026-12-31 |
$-0.20 | $-0.20 | $-0.20 | 89.4% | +66.7% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.80 | $-0.95 | $-0.64 | 77.5% | -12.5% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.010 | |
| 7d ago | $-0.180 | +0.170 |
| 30d ago | $-0.180 | +0.170 |
| 60d ago | $-0.180 | +0.170 |
| 90d ago | $-0.150 | +0.140 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 15, 2026 | Citizens | INITIATE | — | Market Outperform |
| Mar 12, 2026 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| May 1, 2026 | 2 | 4 | 3 | 0 | 0 | 67% | |
| Apr 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
other
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategy <
May 18, 2026
other
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
<p>BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focuse
May 11, 2026
earnings_calendar
NERV Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
earnings_calendar
NERV Q1 2026 Earnings Scheduled — 2026-05-06
May 5, 2026
earnings
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
<p align="center"><em>Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened</em></p>
Apr 2, 2026
other
Minerva Announces Leadership Transition
Jim O’Connor joins as Chief Business Officer and General Counsel <pre>Jim O’Connor joins as Chief Business Officer and General Counsel</pre>
Mar 31, 2026
fda
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
<p align="center"><em>Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug
Mar 25, 2026
fda
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
<p align="center"><em>Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine</em></p>
Mar 12, 2026
other
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
<p>BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focu
Mar 11, 2026
earnings
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipate
Mar 10, 2026
earnings_calendar
NERV Q4 2025 Earnings After Market Close — 2026-03-10